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Abstract

INTERLEUKIN-6 LEVELS IN GENERALIZED AND LOCALIZED AGGRESSIVE
PERIODONTITIS PATIENTS
By Bindu Reddy, D.D.S.
A thesis submitted in partial fulfillment of the requirements for the degree of Master of
Science at the Virginia Commonwealth University
Virginia Commonwealth University, 2004
Major Director: Joseph V. Califano, D.D.S., Ph.D.
Associate Professor, Department of Periodontics

Periodontitis is an inflammatory disease involving the supporting structures of the
dentition. Many studies have shown that there is a relationship between periodontal
disease, the presence of pro-inflammatory cytokines, and systemic disease such as
cardiovascular disease and diabetes mellitus. The purpose of this study was to measure
serum Interleukin-6 levels in generalized and localized aggressive periodontitis and nonperiodontitis patients and look for relationships with measures of disease severity. We
also examined variables known to have a relationship with IL-6. A total of 172 subjects,
comprising three periodontal subgroups, non-periodontitis (NP=61), generalized

aggressive periodontitis (GAP=77), and localized aggressive periodontitis (LAP= 34),
had serum samples evaluated for IL-6 levels using a highly sensitive ELISA test. The IL6 levels were compared with clinical and demographic data including age, race, gender,
number of teeth, probing depth, attachment loss, bleeding index, plaque index, gingival
index, cotinine levels, smoking status, and CRP levels.

Using multiple regression

analysis, smoking status (p=0.0015) was the only variable found to have a significant
relationship with IL-6 levels for all three groups.

Introduction

Periodontitis is an inflammatory disease involving the supporting structures of the
dentition including the cementum, bone, and periodontal ligament.

The initial

presentation of the disease is localized to the gingival sulcus and coronal connective
tissue. However, the disease process, if allowed to progress, can result in periodontal
attachment loss and bone destruction.1 Approximately 50% of the United States
population has gingivitis around three or four teeth at any given time and 35% have
periodontitis defined by the presence of one or more teeth with attachment loss and
probing depth ≥ 3mm.2
Juvenile periodontitis, which we now classify under aggressive periodontitis, is a
term which is defined by Baer3 as a disease of the periodontium occurring in an otherwise
healthy adolescent which is characterized by rapid loss of alveolar bone about more than
one tooth of the permanent dentition. There are two basic forms in which it occurs. In
the localized form, the only teeth affected are the first molars and incisors. In the
generalized form, it may affect most of the dentition.4 According to Baer, the amount of
destruction is not related to the local irritants or amount of plaque present.3 However,
Burmeister et al.5 refute this idea and have reported a positive correlation between plaque
present

and

the

degree

of

destruction

seen

in

aggressive

cases.

Using

the 1991 National Institute of Dental Research national survey, Löe and Brown reported
that the prevalence of localized juvenile periodontitis was 0.53% and generalized juvenile
periodontitis was 0.13%. Males were slightly more likely to have the localized form of
the disease, with blacks more likely than whites to have either form.6
Both chronic and aggressive forms of periodontitis are characterized by
inflammation. Phagocytic cells are recruited to the site of infection through the release of
cytokines and other inflammatory mediators. These cytokines include interleukin-1 (IL1), interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-12 (IL-12), and tumor necrosis
factor α (TNF-α). All of these mediators have important local and systemic effects.
The inflammation and destruction which comprise periodontal disease result from
the host immune response to bacterial challenge. Bacteria and bacterial components such
as lipopolysaccharide (LPS) result in the production of inflammatory mediators, such as
cytokines, by activated macrophages and fibroblasts present in periodontitis lesions.7,8
Several

bacteria

including

Actinobaccilus

actinomycetemcomitans

(Aa)

and

Camphylobacter rectus (Cr) have been shown to amplify human host inflammatory
reactions mediated by pro-inflammatory cytokines, including IL-6 and IL-8.9 There have
been several other pro-inflammatory cytokines implicated in the immunopathology of
periodontitis, with the most convincing evidence for destruction of the periodontium for
Interleukin-1

beta

(IL-1β),10,11,12,13 and

TNF-α.14,15,16 Elevated

levels

of

pro-

inflammatory cytokines have been found in inflamed periodontal tissues and
systemically.17,18,19 Due to the presence of bacterial plaque and cytokine activation, an
inflammatory response occurs which may have global consequences throughout the body.

The cytokines IL-1, IL-6, and TNF-α are key mediators in inflammation. These
cytokines cause systemic effects such as increased body temperature, neutrophil
mobilization, and increased lymphocyte activation.20 They are of particular importance
due to their role in the acute-phase response.20 This response involves the release of
proteins by hepatocytes such as C-reactive protein (CRP) and mannan-binding lectin.21
These two proteins are capable of initiating complement activation and opsonization of
target bacteria.20 Thus, the presence of molecules such as IL-1, IL-6, TNF-α, and CRP
has become a marker of inflammation and the initiation of host defense mechanisms.
Cytokines play an important role in the pathophysiology of chronic inflammatory
diseases, including periodontitis. IL-6 in particular is a major mediator of the host
response to tissue injury, infection, and bone resorption. 20 IL-6 is a critical component of
the acute-phase response because it triggers the release of CRP which is involved in
immune response and pro-inflammatory host reactions. 20
The role of IL-6 and periodontal bacteria, specifically, has been examined. One
such study by Kesavalu et al.22 looked at murine tissue expression of pro-inflammatory
cytokines TNF-alpha, IL-6, and IL-1 beta in response to challenge with periodontal
pathogens

such

as

Porphyromonas

gingivalis

(Pg)

and

Actinobacillus

actimomycetemcomitans (Aa). Results of the study showed that both Pg and Aa elicited
elicited expression of all three cytokines with Pg being more potent than Aa in inducing
cytokine expression. In another study by Nakamura et al.,23 blood samples from seven
healthy subjects were treated with Aa lipopolysaccharide (LPS) and tested for IL-6 and
IL-1 beta expression. Blood cells pre-treated with Aa LPS showed increased production
of IL-1 beta and IL-6 compared to non-LPS pre-treated cells. Also, further analysis

showed that the monocyte fraction of the blood was mostly responsible for the increased
cytokine production seen.

Collectively, this data shows that tissues do respond to

bacteria and their byproducts by mounting an inflammatory reaction which includes
activation of inflammatory cells and production of inflammatory cytokines.
Barthold et al.18 examined IL-6 production by human gingival fibroblasts using
immunohistochemistry. In the study, they were able to localize IL-6 production within
the connective tissue and lower portions of gingival epithelium. They found that areas of
inflammation showed a much more intense staining for IL-6 and concluded that there
may be an association between this inflammatory cytokine and periodontal disease. In
another study by Chen et al.,24 levels of IL-6 and IL-1 beta were examined in both the
gingival tissue and serum of patients with periodontal disease and of periodontally
healthy patients. The levels of both cytokines were measured by ELISA. A positively
significant relationship was found between levels of IL-6 and clinical assessments of
periodontal destruction. IL-6 levels were found to increase in tissues of periodontitis
patients.
Many studies have shown a correlation between periodontitis and systemic
disease

involving

cytokines

inflammation.25,26,27,28,29,30,31,32,33

such

as

IL-6

as

a

shared

mechanism

of

In one such study, gingival crevicular fluid (GCF)

levels of IL-6 were determined in patients with type II Diabetes Mellitus (T2DM) with
periodontitis, adult periodontitis, and healthy controls. The mean GCF IL-6 levels were
highest in T2DM patients with periodontitis, followed by the adult periodontitis patients
with the healthy controls having the lowest levels.25 These findings suggest that GCF IL6 levels were significantly higher in areas of inflammation and periodontal destruction.

Studies by Offenbacher et al.26 have shown a relationship between periodontal
disease and pre-term low birth weight (PLBW) infants. The inflammatory mediators that
occur in periodontal disease also play a significant role in the initiation of labor and
provide a plausible mechanism which may link the two together.

Lopez et al.27

investigated whether the maintenance of a mothers’ periodontal health after 28 weeks
gestation reduced the risk of PLBW infants. They found that the incidence of PLBW was
2.5% in periodontally healthy women, and 8.6% in women with periodontal disease
(p=0.0004).
In the Physician’s Health Study, Ridker et al.28 found elevated levels of IL-6 in
apparently healthy males predicted up to a 2.3-fold increase in myocardial infarction over
6 years. Among these men, the number of risk factors at baseline was correlated with the
plasma concentration of IL-6. In another study, Ridker et al. 29 also reported that baseline
IL-6 levels have been found to predict cardiovascular events in the Women’s Health
Study. Bermudez et al. 30 discuss several clinical cardiovascular risk factors which are
related to circulating plasma levels of IL-6 and CRP in women. Specifically, age, BMI,
smoking status, systolic blood pressure, alcohol use, presence of diabetes, and exercise
frequency are all independent correlates of circulating plasma concentrations of IL-6.
Ciancio31 reports many risk factors which are associated with both periodontal
disease and cardiovascular disease including age, smoking, diabetes, obesity, stress and
diet.

According to Ciancio practitioners must consider these shared risk factors in

diagnosing and treating periodontal disease. In addition to these associations, a pathway
relating oral conditions with cardiovascular disease is discussed by Joshipura et al.32
whereby periodontal disease can lead to increased tooth loss and inflammation followed

by dietary changes, stress, vascular injury, bacteremia and possible coronary vascular
disease outcomes such as endocarditis, stroke and coronary heart disease. Iacopino and
Cutler33 show a linkage between infection and hyperlipidemia. In this model chronic
periodontitis and/or acute infection cause bacteremia and endotoxemia which leads to
increased serum pro-inflammatory cytokine production.

The cytokines then cause

enhanced lipogenesis and reduced lipid clearance with a resultant increase in free fatty
acids, LDL, and triglycerides. This model is cyclic in nature and as lipid levels are
further elevated, periodontitis is exacerbated leading to worse inflammation and lipid
levels.
Although an exact causal mechanism has not yet been determined, the risk factors
and associations between periodontal disease and systemic disease are strong. The key
underlying shared characteristic is inflammation. Based on the biology of inflammation
we know that pro-inflammatory cytokines are major mediators involved in inflammatory
changes throughout the human body. IL-6 has been found in inflamed periodontal tissues
at increased levels compared to healthy tissues. Several studies have demonstrated local
increases in IL-6 levels in gingival crevicular fluid and gingival tissues in response to
periodontitis.18,24,25,34,35,36

However, at present, there is no published data which

correlates serum levels of IL-6 with periodontal disease and oral inflammation. Thus,
there is a need for studies examining the relationship between systemic IL-6 serum
concentrations and periodontitis as well as studies on the effect of periodontal therapy on
serum IL-6 concentrations. This information is of particular importance due to the
potential therapeutic implications and close relationship between periodontal disease and
systemic disease.

HYPOTHESIS: IL-6 levels are elevated in the serum of certain patient groups
with periodontal disease. There is a link between inflammatory systemic conditions and
the periodontal oral inflammation. Periodontal therapy could potentially help to alleviate
and ameliorate certain inflammatory systemic diseases and their symptoms. The purpose
of this study is to measure IL-6 serum levels in generalized and localized aggressive
periodontitis patient populations and healthy controls and determine if there is a
relationship between this variable and measures of periodontal health. We also will
examine additional variables known to relate to IL-6 levels.

Materials and Methods

Patient Selection and Clinical Examination
All subjects were taken from the VCU Clinical Research Center for Periodontal Disease
Database. The database included patients referred to the center and patients identified
from the dental population at VCU School of Dentistry. All patients signed an informed
consent form approved by VCU Committee on the Conduct of Human Research. A total
of 172 subjects had a medical history obtained by questionnaire and interview, complete
dental exam, and matching serum samples with clinical exam. Complete exams consisted
of suppuration index, plaque index (APLI),37 gingival index (AGI),38 pocket depth (PKT
Avg), bleeding index (ABI), attachment loss measurements (Aloss), and tooth mobility.
Missing and deciduous teeth were also recorded. Smoking status, cotinine levels, CRP
levels were also measured. Clinical exam was measured at 4 sites per tooth (mesiobuccal, buccal, distal-buccal, and lingual) with a Hu-Friedy color-coded probe (PCP 12).
Diabetic subjects and subjects with reported arthritis were eliminated from the database.
All examiners performing exams were calibrated to verify examiner reliability.39

Subject Groups
Aggressive Periodontitis. Encompasses distinct types of periodontitis that affect people
who, in most cases, otherwise appear healthy. It tends to have a familial aggregation and
there is a rapid rate of disease progression.

Aggressive periodontitis occurs in

generalized and localized forms.
Generalized Aggressive Periodontitis- A total of 77 subjects showing a
generalized pattern of severe periodontal destruction with attachment loss of at
least 5 mm on eight or more teeth, at least 3 of which are not first molars and
incisors. Subjects ranged in age from 12 to 67 years.

Localized Aggressive Periodontitis- A total of 34 subjects. Clinical attachment
loss pattern—must have at least 4 mm attachment loss (Aloss) on at least 2
permanent first molars and incisors (at least one molar must be affected) and no
more than 2 teeth, which are not first molars or incisors that are affected by 5 mm
AL or more. Subjects ranged in age from 8 to 46 years.

Non-Periodontitis (NP). A total of 61 subjects with no evidence of attachment loss at
more than one site, except for recession on the buccal of anterior teeth, or pockets greater
than 3 mm.

That is, no detectable periodontitis; healthy periodontium.

Gingival

inflammation may be present in variable degrees of severity. Subjects ranged in age from
6 to 50 years of age.

IL-6 Assay
96-well microtiter plates were used which were coated with antibody for human IL-6.
Standard serial dilutions of recombinant human IL-6 were prepared with a standard
diluent 0.1% (w/v) sodium azide. IL-6 levels ranged from 0.63-20 pg/ml. 100µl of
standard diluent was loaded into designated wells and 100 µl of sample was loaded into
the appropriate wells on the 96 well microtiter plates. Plates were then covered and
stored for 2 hours at room temperature (20-25°C) with continuous shaking. After this
incubation period, each well was aspirated and washed thoroughly with wash buffer for a
total of four washes. Complete liquid removal was assured after each wash step. After
the wash cycles, 100 of biotinylated antibody reagent was pipetted into all wells. Plates
were again covered and incubated for 30 minutes at room temperature (20-25°C) with
continuous shaking. The wash and aspiration cycle was again repeated four times as
described above. Next 100 µl of Amdex amplification reagent was added to all wells.
Plates were covered with new adhesive strips and and incubated for 30 minutes at room
temperature (20-25°C) with continuous shaking. The wash and aspiration cycle was
again repeated four times as described above. Finally 100 µl of TMB substrate was
added to each well and incubated for 30 minutes at room temperature (20-25°C) with
continuous shaking. Plates were not covered during this step. Following the 30 minute
incubation, 100 µl of stop solution was added to each well. Optical density was then
determined for each well within 30 minutes using a spectrophotometer set to 450nm. The
duplicate readings for each standard and sample were averaged and the zero standard
optical density was subtracted from each value.

Statistical Analysis
One way ANOVA and bivariate analysis were used to calculate the significance of IL-6
levels against various continuous and dichotomous variables including race, sex, number
of teeth, pocket depth (PKT Avg), attachment loss (Aloss), plaque index (APLI), gingival
index (AGI), bleeding index (ABI), reported smoking status, cotinine levels, and CRP
levels within each subject group. Multiple regression was used to calculate significance
of IL-6 levels against these variables for all three subject groups combined.

A

significance level of 0.05 was used. Stepwise regression was then performed using
variables which approached significance with p< 0.2.

Results

Patient demographics and parameter means are given in Tables 1 and 2. Table 1
shows mean values and standard errors of the continuous variables measured for each
subject group. Table 2 shows percentages for dichotomous variables measured for each
subject group.
We compared the IL-6 levels in each patient group to the variables found in
Tables 1 and 2 (Table 3). In Table 3, a statistically significant correlation was found
between IL-6 levels and smoking status within the LAP patient group (p<0.0001). No
other significant differences were found.
We then combined the data for all 3 groups and examined the relationship
between IL-6 and the variables in Tables 1 and 2 including attachment loss and
periodontal classification (Table 4). Non-smokers had significantly lower IL-6 levels
(odds ratio= -3.11, p= 0.0024) and smokers had significantly higher IL-6 levels (odds
ratio= 3.26, p= 0.0015) (Table 4). A trend was noted between LAP periodontal status
and IL-6 levels (odds ratio=1.88, p=0.0627) (Table 4). No significant results were noted.
Stepwise regression analysis was used for factors which approached significance
using p< 0.2. The three variables tested were LAP status, smoking, and plaque index.
Results showed that smokers again had significantly elevated IL-6 levels (p< 0.0001).

LAP patients showed increased IL-6 levels, but results were still not significant
(p=0.0587). Plaque index was not significant (p=0.1302).

Table 1
Mean Values of Continuous Variables Measured for Patient Subgroups

Age
Number of Teeth
PKT Avg
Aloss
APLI
AGI
ABI
Cotinine
IL-6 mean
CRP mean

LAP
22.7
26.970588
2.6369407
0.6489857
0.8624218
1.173042
0.3527414
64.909524
3.5356176
3.6125882

±Std error
±0.415
±0.095
±0.075
±0.084
±0.064
±0.038
±26.597
±2.015
±0.638

GAP
31.3
24.571429
3.437879
2.5871881
1.2406649
1.3570198
0.4450448
202.22466
1.258987
3.7772987

±Std error
±0.640
±0.101
±0.180
±0.057
±0.048
±0.027
±34.115
±0.252
±0.390

NP
31.0
27.508197
2.0684114
0.2468588
0.5018255
0.6055005
0.1833749
35.3785571
2.2888852
1.5823607

Table 2
Dichotomous Variables Measured for Patient Subgroups

Race
Sex
Smoker

Black
White
Male
Female
Yes
No

LAP
0.76471
0.20588
0.41176
0.58824
0.32353
0.67647

GAP
0.62338
0.37662
0.33766
0.66234
0.62338
0.37662

NP
0.22951
0.77049
0.52459
0.47541
0.52459
0.47541

±Std error
±0.352
±0.256
±0.036
±0.055
±0.047
±0.025
±20.694
±1.071
±0.270

Table 3
IL-6 Levels of Patient Subgroups Based on Variables Measured

Race
Sex
Number of Teeth
PKT Avg
Aloss
APLI
AGI
ABI
Cotinine
Smoking Status
CRP

P-Values
LAP
0.5072
0.8914
0.5158
0.6975
0.5770
0.1127
0.5825
0.8210
0.6725
<0.0001*
0.1000

GAP
0.3416
0.2048
0.3443
0.2397
0.6487
0.1284
0.9129
0.5060
0.4536
0.4584
0.7714

NP
0.5217
0.9591
0.8787
0.7560
0.4245
0.9062
0.5224
0.5375
0.6687
0.1190
0.3630

*Statistically significant P values obtained by bivariate analysis

Table 4
Significance of Variables on IL-6 Levels-Comparisons Across
All Patient Subgroups

Class (LAP)
Class (GAP)
Class (NP)
Race (Black)
Sex (F)
Number of Teeth
PKT Avg
Aloss
APLI
AGI
ABI
COTININE
Smoker (Y)
Smoker (N)
CRP mean

t ratio
1.88
-0.18
-0.39
-0.32
-0.42
-0.36
0.50
-0.35
-1.58
0.58
-0.04
-0.21
3.26
-3.11
-0.01

Prob>t 
0.0627
0.8600
0.6958
0.7469
0.6759
0.7214
0.6172
0.7308
0.1173
0.5614
0.9700
0.8377
0.0015*
0.0024**
0.9941

*statistically significant increase in IL-6 levels
**statistically significant decrease in IL-6 levels

Discussion

In this study we examined the relationship of IL-6 and measures of periodontal
disease in LAP and GAP patients. We also examined variables known to relate to IL-6,
including CRP. The only variable which was significantly related to IL-6 levels was
smoking. It is not surprising that smoking was found to be significantly correlated to
increased IL-6 levels.

Several studies have also shown the mechanisms by which

smoking may affect the periodontium including PMN chemotaxis problems, increased
proportions of harmful periodontal microflora, increased bone andattachment loss, and
poor wound healing.40,41,42,43,44,45,46,47,48

Tomar et al.49 researched the NHANES III

database and found that current smokers were about 2-3 times as likely as non-smokers to
have periodontitis.

The odds ratios ranged from 2.79 for those who smoked < 10

cigarettes/day to 5.88 for those who smoke >30/day. They also calculated that smoking
cigarettes may be responsible for over 50% of the cases of periodontitis among adults in
the United States. Grossi et al.46,47 assessed risk indicators for alveolar bone loss and
attachment loss. They found that smokers had greater odds ratios than non-smokers for
bone loss ranging from 3.25 for light smokers to 7.28 for heavy smokers and attachment
loss ranging from 2.05 for light smokers to 4.75 for heavy smokers. These odds ratios
are similar to the odds ratio we found between smoking and IL-6 of 3.26.

Giannopoulou et al.36 looked at the effects of smoking and inflammation on
gingival crevicular fluid cytokine levels in 40 patients with aggressive and chronic
periodontitis and 20 patients with gingivitis compared to 20 healthy controls. They found
that IL-6, IL-8 and IL-1 beta levels were significantly elevated in peridontally diseased
subjects compared to healthy controls. They also reported that IL-4, IL-6, IL-8 and IL-1
beta were all positively correlated with probing depths. IL-4, IL-6 and IL-8 were found to
be correlated to smoking. Therefore, we can see the relationship between smoking,
inflammation, and periodontal destruction as evidence and support for our findings.
We noted that amongst the three subject groups, LAP status showed an increased
odds ratio (t ratio=1.88, p=0.0627) of elevated IL-6 levels. The literature shows a
relationship between inflammation and clinical parameters of periodontitis such as
bleeding and increased probing depths which may explain this correlation.50,51,52 Studies
by Caton et al.52,53 and Davenport et al.54 have shown that bleeding is indicative of
histologic inflammatory changes occurring within the tissues. Bleeding on probing along
with suppuration or increased probing depths can be predictive of future attachment
loss.50,51

A 2002 VCU Master’s thesis project by Fernandez55 also examined the

relationship between periodontal disease (local inflammation) and cardiovascular disease
(systemic inflammation) using the NHANES III database. Results of the project showed
that gingival bleeding was significantly related to a history of non-fatal heart attack with
an odds ratio of 1.95. Discussion related bleeding to periodontal inflammation and the
possible role of pro-inflammatory cytokines in leading to further systemic inflammation.
A study by Willerhausen et al. 56 shows that there is a correlation between inflammatory
periodontal disease and cardiovascular disease. They found that mean bleeding index

was significantly higher in coronary heart disease patients compared to healthy controls.
Based on these previous studies we can see a possible relationship between clinical
periodontitis and inflammation and would expect to see increased pro-inflammatory
cytokines such as IL-6.
IL-6 is part of the acute phase response and causes CRP to be released by
hepatocytes, which is then involved in initiating complement activation and opsonization
of target bacteria. 20 We noted a correlation between LAP status and IL-6 cytokine levels.
However, results did not show any increase or significance in IL-6 levels when measured
against CRP in any of the subgroups. D’Aiuto et al. 57 conducted a pilot study on 94
subjects and assessed serum CRP and IL-6 levels at baseline and at 2 and 6 months
following non-surgical periodontal therapy. They found significant reductions in CRP
and IL-6 serum levels along with improvement in all clinical periodontal parameters with
therapy.

In another related study, Loos et al.

58

looked at CRP and IL-6 levels in

periodontitis patients. They examined 53 localized periodontitis patients, 54 generalized
periodontitis patients and 43 healthy controls and found significantly higher mean levels
of CRP and IL-6 in periodontitis patients compared to controls. They also found that
CRP and IL-6 correlated with each other, and both correlated with the number of
neutrophils in the peripheral blood samples of the periodontitis patients. We would
expect to see a correlation between IL-6 and CRP in the subjects. However, in our study,
we did not note such a correlation.
It is possible that the reason we failed to find relationships for IL-6 reported by
others was due to degradation or denaturation of the IL-6 in the samples used for our
experiments. In our study, the serum samples were obtained over the last 20 years and

some have been repeatedly thawed and frozen during ongoing projects. We suspect that
there may have been a problem with the stability of IL-6 in the sample serum. Kenis et
al.

59

examined the stability of IL-6 in human serum under varying conditions. They

looked at the concentration of serum IL-6 stored at 4ºC, 20ºC, 30ºC, and 40ºC for 1 to 21
days compared to triplicate samples of the same person frozen at -20ºC. They found that
recovery of IL-6 did not decrease for up to 21 days at 4ºC, 20ºC or 30ºC and only
decreased after 21 days at 40ºC. They found that the concentration of IL-6 did not
change when incubated at 4ºC or 20ºC for up to 4 days before centrifugation. They also
found that up to four repeated freeze-thaw cycles did not influence recovery of IL-6 in
their study. These results do not corroborate those from Flower et al. 60 who found that
IL-6 concentrations were affected by various treatments prior to experimental use.
Serum samples were obtained from healthy subjects and examined for IL-6 levels under
many conditions: (i) standing for 1, 2, 4, or 6 h prior to, or after separation, before
freezing at -70 degrees C; (ii) taken into tubes with different anticoagulants or no
anticoagulant, separated and frozen; and (iii) separated, and repeatedly freeze-thawed for
up to six cycles prior to assay. Results showed that storage conditions can significantly
alter the concentrations of the molecules and need to be standardized. Also, the type of
anticoagulant used and the number of freezing cycles may alter the concentration of
cytokines and should be considered when studies are being conducted. Another study by
Thavasu et al. 61 looked at blood cytokine levels of many cytokines including IL-6 under
different anticoagulant, processing, and storage conditions. The study showed that the
stability and recovery of the cytokines was affected by the varying study parameters.
Handling methods did influence cytokine levels. The recovery of IL-6 from serum

samples was found to be consistently lower than the amount recovered from plasma
samples. Therefore, the properties and concentrations of the cytokine in the samples may
have been altered by the treatment of the samples prior to use.
Interestingly, Sothern et al.62,63 conducted two studies which examined the
circadian characteristics of IL-6 in blood and urine samples of clinically healthy men.
Because most human biologic activities and functions are governed by circadian rhythms,
this group tested the activity of IL-6 during various daytime and nighttime hours. They
found that average IL-6 values ranged from 1.66 to 5.38 pg/ml, with the lowest to highest
values within 24 hours ranging from 1.20 to 7.58 pg/ml between subjects. On average,
values were greater than the mean throughout the night, with a peak at 01:00 hours and
less than the mean throughout the day, with the lowest value at 10:00 hours. The
opposite trend was found for urine IL-6 levels with the highest values found during the
day and the lowest values found at night. A significant time effect was found by
ANOVA. They suggested that endogenous IL-6 levels may be significantly altered by
their large day-night variations and the type of fluid collected. In our study, subjects
were seen in the clinics during the daytime, during office hours only. Therefore, it is
possible that IL-6 serum concentrations were affected by collection times.
In future studies, we will collect samples and use them within a given time period.
Storage and processing protocols must be carefully laid out ahead of time. We will also
avoid repeated freezing and thawing of samples for use. Samples should be aliquoted in
small amounts so that fresh sample tubes could be used for each experiment and
contamination would be avoided. We will thus possibly prevent some product loss due to
improper handling conditions. It would also be interesting to investigate the relationship

between collection time and serum IL-6 concentrations in our patient population. Finally,
in light of these past studies, it would seem wise to standardize collection times to certain
parts of the day in order to prevent bias in the results.
We hypothesized that serum IL-6 concentrations, like gingival tissue
concentrations,18,24 would be increased and directly related to periodontal breakdown and
disease in our patient population.

The study by Loos et al.58 previously discussed

examined levels IL-6 and CRP in the peripheral blood of periodontitis patients. They
found that CRP, IL-6 and neutrophil levels were elevated in periodontitis patients. The
elevated pro-inflammatory markers may be related to the inflammation seen in
cardiovascular disease and may lead to an increased risk for cardiac sequellae such as
development of atherosclerotic lesions in this patient population. If there is indeed a
relationship between systemic inflammation, cardiovascular disease, and periodontitis,
then therapeutic measures aimed at reducing periodontal inflammation are warranted. In
the future we would like to examine the relationship between periodontal therapy and
serum IL-6 concentrations and hope to see that therapy will help in reducing the amount
of this pro-inflammatory cytokine within the patient’s system. Perhaps we can then
explain a causal relationship amongst systemic inflammation, cardiovascular disease, and
periodontal disease.
Some recent studies have investigated different avenues of therapy for combating
periodontal inflammation and perhaps subsequent systemic inflammation. In a study by
Tipton et al.,64 the role of cyclooxygenase-2 (COX-2) inhibitors in periodontal therapy
was examined. Gingival fibroblasts were cultured in medium with IL-1 beta, with or
without COX-2 inhibitors. Results showed that COX-2 inhibitors caused dose-dependent

decreases in PGE-2 and IL-6 production by IL-1 beta stimulated gingival fibroblast and
may be useful in controlling inflammation in these patients. Thus, a link is shown
between systemic therapy and treatment of periodontitis. In a study last year, Takashiba
et al.65 discussed a possible role for anti-cytokine therapy, such as anti-IL-6 antibodies, in
combating periodontal inflammation. If a direct relationship is found among serum
levels of IL-6 and other inflammatory cytokines and periodontitis on a systemic level
then systemic therapy such as vaccinations may be possible and warranted.
In this study, a significant correlation was found between serum IL-6 levels and
smoking status. Also, a trend was noted between LAP periodontal status and IL-6 levels.
Our future studies will aim to repeat this work with standardized handeling of serum
samples as described above. We will also examine the relationship of periodontal therapy
and IL-6 levels in patients with chronic and aggressive periodontitis.
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